Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 9/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461636 | 0.88 | GRM2 (0.36) | ROCK2CCR5GRM2HSD11B1DRD2 | |
| SCHEMBL5072825 | 0.88 | GRM2 (0.41) | ROCK2CCR5GRM2EBPKCNH2 | |
| SCHEMBL30623501 | 0.79 | GRM2 (0.36) | ROCK2GRM2DRD2 | |
| SCHEMBL2476693 | 0.78 | EBP (0.43) | ROCK2EBPHSD11B1KCNH2GBA1 | |
| SCHEMBL5072452 | 0.78 | HTR2A (0.40) | — | |
| Hydrochloric Acid SCHEMBL3228128 | 0.77 | GRM2 (0.36) | GRM2DRD2 | |
| SCHEMBL4461624 | 0.75 | GRM2 (0.44) | ROCK2CCR5GRM2HSD11B1 | |
| SCHEMBL6621733 | 0.71 | ACE (0.33) | HSD11B1 | |
| SCHEMBL12184284 | 0.70 | GABRP (0.36) | GRM2HSD11B1 | |
| SCHEMBL15000803 | 0.68 | KDM4E (0.33) | ROCK2EBPGBA1CYP11B2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | ROCK2 4451/4885CCR5 1/4885GRM2 655/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | ROCK2 4451/4885CCR5 1/4885GRM2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.